Proteome Sciences Gestione

Gestione criteri di controllo 4/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Mariola Sohngen

Amministratore delegato

UK£261.0k

Compenso totale

Percentuale dello stipendio del CEO	95.4%
Mandato del CEO	4.2yrs
Proprietà del CEO	n/a
Durata media del management	7.3yrs
Durata media del Consiglio di amministrazione	7.3yrs

Aggiornamenti recenti sulla gestione

Here's Why Shareholders Should Examine Proteome Sciences plc's (LON:PRM) CEO Compensation Package More Closely

May 10

Recent updates

Here's Why Shareholders Should Examine Proteome Sciences plc's (LON:PRM) CEO Compensation Package More Closely

May 10

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Mariola Sohngen rispetto agli utili di Proteome Sciences?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	n/a	n/a	-UK£4m
Mar 31 2024	n/a	n/a	-UK£3m
Dec 31 2023	UK£261k	UK£249k	-UK£2m
Sep 30 2023	n/a	n/a	-UK£879k
Jun 30 2023	n/a	n/a	UK£684k
Mar 31 2023	n/a	n/a	UK£1m
Dec 31 2022	UK£310k	UK£247k	UK£1m
Sep 30 2022	n/a	n/a	UK£943k
Jun 30 2022	n/a	n/a	UK£560k
Mar 31 2022	n/a	n/a	UK£316k
Dec 31 2021	UK£258k	UK£235k	UK£72k
Sep 30 2021	n/a	n/a	UK£228k
Jun 30 2021	n/a	n/a	UK£384k
Mar 31 2021	n/a	n/a	UK£340k
Dec 31 2020	UK£252k	UK£73k	UK£295k

Compensazione vs Mercato: La retribuzione totale di Mariola ($USD 328.74K ) è circa la media per le aziende di dimensioni simili nel mercato UK ($USD 356.31K ).

Compensazione vs guadagni: La retribuzione di Mariola è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Mariola Sohngen (63 yo)

4.2yrs

Mandato

UK£261,000

Compensazione

Dr. Mariola Sohngen serves as Chief Executive Officer and Executive Director at Proteome Sciences plc since September 15, 2020. Dr. Söhngen served as a Member of the Executive Board of Mologen AG since Nov...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Mariola Sohngen	CEO & Executive Director	4.2yrs	UK£261.00k	Nessun dato
Abdelghani Omari	CFO & Director	2.2yrs	UK£212.00k	Nessun dato
Ian Pike	Chief Scientific Officer & Executive Director	7.9yrs	UK£245.00k	0.056% £ 4.6k
Richard Dennis	Chief Commercial Officer & Executive Director	7.6yrs	UK£207.00k	0.21% £ 17.2k
Victoria Birse	Company Secretary	7.3yrs	Nessun dato	Nessun dato

7.3yrs

Durata media

61.5yo

Età media

Gestione esperta: Il team dirigenziale di PRM è esperto e expertise (durata media dell'incarico 7.3 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Mariola Sohngen	CEO & Executive Director	4.2yrs	UK£261.00k	Nessun dato
Abdelghani Omari	CFO & Director	2.2yrs	UK£212.00k	Nessun dato
Ian Pike	Chief Scientific Officer & Executive Director	14.1yrs	UK£245.00k	0.056% £ 4.6k
Richard Dennis	Chief Commercial Officer & Executive Director	6.6yrs	UK£207.00k	0.21% £ 17.2k
Denis Hochstrasser	Member of the Scientific Advisory Board	no data	Nessun dato	Nessun dato
Christopher Donovan Pearce	Non Executive Chairman	30.3yrs	UK£62.00k	12.51% £ 1.0m
Roger McDowell	Independent Non Executive Director	10.3yrs	UK£35.00k	1.15% £ 93.5k
William Dawson	Chairman of Scientific Advisory Board	no data	UK£16.00k	Nessun dato
Jean-Charles Sanchez	Member of the Scientific Advisory Board	no data	Nessun dato	Nessun dato
Brian Anderton	Member of the Scientific Advisory Board	no data	Nessun dato	Nessun dato
Ursula Ney	Independent Non-Executive Director	7.3yrs	UK£33.00k	Nessun dato
Julian Duncan	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato

7.3yrs

Durata media

66yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di PRM sono considerati esperti (durata media dell'incarico 7.3 anni).

Proteome Sciences Gestione

Gestione criteri di controllo 4/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Proteome Sciences plc Announces Step Down of Dr Mariola Soehngen as Chief Executive Officer at the End of January 2025

Here's Why Shareholders Should Examine Proteome Sciences plc's (LON:PRM) CEO Compensation Package More Closely

Proteome Sciences plc, Annual General Meeting, May 16, 2024

Less than half of directors are independent

Proteome Sciences plc Appoints Abdel Ghani Omari as the Company's New Chief Financial Officer

Less than half of directors are independent

Recent updates

New major risk - Market cap size

New major risk - Market cap size

New major risk - Revenue and earnings growth

Proteome Sciences plc Announces Step Down of Dr Mariola Soehngen as Chief Executive Officer at the End of January 2025

Here's Why Shareholders Should Examine Proteome Sciences plc's (LON:PRM) CEO Compensation Package More Closely

New major risk - Share price stability

Full year 2023 earnings released: UK£0.008 loss per share (vs UK£0.004 profit in FY 2022)

Proteome Sciences plc, Annual General Meeting, May 16, 2024

New minor risk - Financial data availability

New major risk - Share price stability

Here's Why We Think Proteome Sciences (LON:PRM) Is Well Worth Watching

Proteome Sciences plc Announces the Launch of Sysquant® SCP, the Commercial Service for Single Cell Proteomics Using the Power of its TMTpro™ Isobaric Labelling Reagents

First half 2023 earnings released: UK£0.002 loss per share (vs UK£0 in 1H 2022)

Now 43% undervalued

Here's Why Proteome Sciences (LON:PRM) Has Caught The Eye Of Investors

Full year 2022 earnings released: EPS: UK£0.004 (vs UK£0 in FY 2021)

Here's Why Proteome Sciences (LON:PRM) Has Caught The Eye Of Investors

Less than half of directors are independent

Do Proteome Sciences' (LON:PRM) Earnings Warrant Your Attention?

Proteome Sciences plc Appoints Abdel Ghani Omari as the Company's New Chief Financial Officer

First half 2022 earnings released

Proteome Sciences plc Completes Milestone Towards Launch of single Cell Proteomics Services

Less than half of directors are independent

Full year 2021 earnings released: EPS: UK£0 (vs UK£0.001 in FY 2020)

Proteome Sciences plc, Annual General Meeting, May 16, 2022

Now 25% undervalued after recent price drop

Proteome Sciences plc to Report Fiscal Year 2021 Results on Mar 31, 2022

Now 21% undervalued after recent price drop

Now 23% undervalued after recent price drop

Proteome Sciences plc Provides Earnings Guidance for the Financial Year Ended 31 December 2021

Calculating The Fair Value Of Proteome Sciences plc (LON:PRM)

First half 2021 earnings released: UK£0.001 loss per share (vs UK£0.002 loss in 1H 2020)

Does Proteome Sciences (LON:PRM) Deserve A Spot On Your Watchlist?

Some Confidence Is Lacking In Proteome Sciences plc's (LON:PRM) P/E

Full year 2020 earnings released: EPS UK£0.001 (vs UK£0.001 in FY 2019)

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media